Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax - Test2 - elhamkhani - TriplyDB

Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax

Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax

http://www.wikidata.org/entity/Q24682011

about

Anthrax prophylaxis: recent advances and future directions Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs Crystal Structure of the Engineered Neutralizing Antibody M18 Complexed to Domain 4 of the Anthrax Protective Antigen CD4+ T Cells Targeting Dominant and Cryptic Epitopes from Bacillus anthracis Lethal Factor Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection An overview of anthrax infection including the recently identified form of disease in injection drug users Anthrax vaccination strategies Monoclonal antibody therapies against anthrax Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model Anthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits.Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy A novel mechanism for antibody-based anthrax toxin neutralization: inhibition of prepore-to-pore conversion.An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor.Cathelicidin administration protects mice from Bacillus anthracis spore challenge Rapid vaccination using an acetalated dextran microparticulate subunit vaccine confers protection against triplicate challenge by bacillus anthracis.Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factor Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.Antibodies against anthrax: mechanisms of action and clinical applications.Development of an in vitro potency assay for anti-anthrax lethal toxin neutralizing antibodies A Novel Chimeric Anti-PA Neutralizing Antibody for Postexposure Prophylaxis and Treatment of Anthrax.Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum.Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization Monoclonal antibodies and toxins--a perspective on function and isotype.Bacillus anthracis cell wall produces injurious inflammation but paradoxically decreases the lethality of anthrax lethal toxin in a rat model.MHC class II and non-MHC class II genes differentially influence humoral immunity to Bacillus anthracis lethal factor and protective antigen.In vivo efficacy of beta-cyclodextrin derivatives against anthrax lethal toxin Characterization of the native form of anthrax lethal factor for use in the toxin neutralization assay.Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies Anti-infective antibodies: a novel tool to prevent and treat nosocomial diseases.Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Synthetic peptide vaccine targeting a cryptic neutralizing epitope in domain 2 of Bacillus anthracis protective antigen.Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding.Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody.The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes.A heterologous helper T-cell epitope enhances the immunogenicity of a multiple-antigenic-peptide vaccine targeting the cryptic loop-neutralizing determinant of Bacillus anthracis protective antigen.Predictive models and correlates of protection for testing biodefence vaccines.Anthrax vaccines: present status and future prospects.Fusion protein of Delta 27LFn and EFn has the potential as a novel anthrax toxin inhibitor.

P2860

Q26781366-E7DB8001-5154-47BF-9CD2-D7D131004A10 Q26863621-863661E0-04EE-437C-A2BD-47D331C3ACF9 Q27654632-0FC5AA36-3A18-4266-B807-6F7162F1436B Q28383022-3486755A-8996-4374-B9F9-E363DEFDD3EE Q28389813-45E65EE0-E9A1-4408-B88E-34A94D170A88 Q28392066-7EF990A3-E303-4EF2-BB52-77ABD632186F Q28392248-4F73E99B-E441-403C-A496-584E8C226BF9 Q28393072-3380236A-8149-4FA6-8E9A-737A0F794B14 Q28748886-ECC6DFE0-EA59-477C-A042-E430C8CB86A6 Q33783323-10F572CC-B7EF-4632-B537-DA54C3FE1CAA Q33936452-30AB6B6D-6F90-45EC-AD5C-D491D4BB4652 Q34025527-E8B8124A-1DA4-47AE-87DE-E4D22DFCF9FD Q34368362-2DCAED4B-FA0D-45BA-8EC5-C4FB89F417AE Q34433313-43F35FE7-0C4A-4B89-B08F-1BB2CD6FEEB1 Q34476038-7980EC08-C966-44FF-850A-04200C67E045 Q34564854-88666001-088D-4C58-93E0-F2443F1B8D92 Q34761514-5593605F-C428-4581-AFED-ECB512AEA4B5 Q35599606-8C348932-88CF-47B6-BD11-662E2C33AA58 Q35610439-8B23443F-BF73-4254-89FF-36EB7CCA3C3A Q35749538-4A4B5423-DD98-43DA-9F29-764966BC06DB Q35808793-5FC98D3A-4BE0-43BA-8F59-C522BD2DB0C8 Q35869311-B5BE6EF4-1687-4AA1-A374-E161DF914C9E Q36007463-A339499D-DFE1-49AD-9195-B92FDBD914D8 Q36099489-B2499A2A-615D-4E6D-9771-1625B53E90C2 Q36108204-7C414E17-451B-438F-A63B-2B44C6EEB818 Q36482706-386BCF14-A0A9-4BEF-843A-66A4BADC572A Q36703020-F9321058-9433-4905-A49B-37722CB10A8F Q36970210-D7F0D0AD-6DD9-4B50-A59B-097C257F29F5 Q37033046-3A7F8877-7FE6-4A6C-8840-B61FC62220BD Q37077611-DFB3F294-1D3E-441C-B07B-76B6A2EF0131 Q37110110-4164214F-23A2-45D6-8127-71174F3855E8 Q37262118-87653730-31F8-41C2-94BD-64DA33470263 Q37274918-8908C631-E8B8-4A1E-8884-84B36F45ED52 Q37304034-33B52360-8C8B-428B-83FE-B64BEB55EA94 Q37333457-33D82057-C67F-4114-96AE-C3A6E751044A Q37410339-F14285D8-6B11-4DA0-A838-61E73CCB324B Q37451219-50A3A6AD-09E3-4D5C-B7EE-5B5D97169BB1 Q37745002-CE9FDC7C-03B9-4638-81DB-2C6AA95B1F22 Q38132268-B59932B9-D2D5-424C-8C5B-3CD3074AFCF7 Q38355454-D32C6DFC-72B4-419A-9988-8739DD772E14

P2860

Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax

http://www.wikidata.org/entity/Q24682011

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

name

Human monoclonal antibodies ag ...... endogenous immunity to anthrax

@ast

Human monoclonal antibodies ag ...... endogenous immunity to anthrax

@en

Human monoclonal antibodies ag ...... endogenous immunity to anthrax

@nl

type

label

Human monoclonal antibodies ag ...... endogenous immunity to anthrax

@ast

Human monoclonal antibodies ag ...... endogenous immunity to anthrax

@en

Human monoclonal antibodies ag ...... endogenous immunity to anthrax

@nl

prefLabel

Human monoclonal antibodies ag ...... endogenous immunity to anthrax

@ast

Human monoclonal antibodies ag ...... endogenous immunity to anthrax

@en

Human monoclonal antibodies ag ...... endogenous immunity to anthrax

@nl

P1433

Q24682011-AD75E3CA-9624-44DA-8D62-E4EB6B04E3EF

P1476

Q24682011-59BD8212-D22B-4614-890F-1CF1024F16F1

P2093

Q24682011-00592EC8-1959-4991-A97A-7FA5D1546D38

Q24682011-25DE02E9-9E21-4EDB-8502-A27AE2EFEA5A

Q24682011-2FE5E83D-0029-48F8-9F34-FA6FF8A3F757

Q24682011-3A36B445-4CBE-4101-AF18-04C713F85636

Q24682011-4C137E31-2F7A-4387-8D07-EDDE89D9E3AE

Q24682011-5E84BE06-4A4A-4702-B934-9E4B96AE87B3

Q24682011-A310AA1E-6228-44F4-8683-4C7BDA1D1602

Q24682011-A8EEBCBB-C788-406D-8757-3DC0BAE05DC1

Q24682011-D2D6B1CC-85F9-4CFE-A927-82948557505B

Q24682011-D2E92023-2C46-4218-BD49-21BE26512AC1

P2860

Q24682011-0E45C1AE-AA6E-4A47-B4A1-30909AB3FFA0

Q24682011-17E52873-7516-4194-B4D9-911067B65646

Q24682011-1E0BF599-729E-4A52-B2E8-8333100BC4AC

Q24682011-202216C7-ACD3-4ECE-9197-3B85BDC51C94

Q24682011-24C13B52-8DFA-43A4-9B68-8AD91F757B8D

Q24682011-252FA08D-8656-45A0-9D3B-F9FB76EC6078

Q24682011-2AD828B8-3148-49C5-B10F-76672B365BED

Q24682011-2CAD2B00-5D7F-4095-B40D-1DE28A64F526

Q24682011-2E2A637C-898B-4786-BFDE-0213DBEA82CC

Q24682011-3016FFC0-FEEB-44D5-8CE1-E1D5B51C2432

P304

Q24682011-642EDB5E-C590-43E6-BD7E-D00BDF90EC3D

P31

Q24682011-69F5B42D-E301-46F9-AD77-F28752CD9292

P356

Q24682011-D1E0A61C-F07C-4E4B-B033-BBFAFF12EC2A

P407

Q24682011-FDFF84D4-64D9-4941-8FA3-AC45C21C460D

P433

Q24682011-32242C0E-17E8-4EE1-BF91-61A8C371AB14

P478

Q24682011-D8A253DF-43B2-42F9-9A4E-C5EA0D0B7738

P50

Q24682011-27DABAFF-295B-4DF1-87CA-323D44629EB8

P577

Q24682011-713EB4C3-2745-4EAD-B6EC-4DF5AE799CDE

P5875

Q24682011-3FD84D34-9F4E-4519-91A9-964FF9EC8914

P698

Q24682011-C9DDF874-523A-4D7E-8EFB-62054CB66BC1

P921

Q24682011-64723872-DAA1-45E5-A60E-D8CEF5D781DA

Q24682011-BA72DEDC-2EDB-42F6-B7EB-299EBF05301B

P932

Q24682011-93E616F5-82FD-4CBB-8A30-B621453BF46F

P356

P1433

Infection and Immunity

P1476

Human monoclonal antibodies ag ...... endogenous immunity to anthrax

@en

P2093

Alfred Mateczun

http://www.w3.org/2001/XMLSchema#string

Chris S LeButt

http://www.w3.org/2001/XMLSchema#string

Darrell Galloway

http://www.w3.org/2001/XMLSchema#string

E Diane Williamson

http://www.w3.org/2001/XMLSchema#string

Han Li

http://www.w3.org/2001/XMLSchema#string

Hans Westra

http://www.w3.org/2001/XMLSchema#string

Helen C Flick-Smith

http://www.w3.org/2001/XMLSchema#string

Herman Groen

http://www.w3.org/2001/XMLSchema#string

Les W J Baillie

http://www.w3.org/2001/XMLSchema#string

Mark T Albrecht

http://www.w3.org/2001/XMLSchema#string

P2860

A model of anthrax toxin lethal factor bound to protective antigen.

Human alpha-defensins neutralize anthrax lethal toxin and protect against its fatal consequences

Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications

Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States

Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor

Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed

Quantitative pathology of inhalational anthrax I: quantitative microscopic findings

Identification of the cellular receptor for anthrax toxin

Observations on experimental anthrax; demonstration of a specific lethal factor produced in vivo by Bacillus anthracis

Identification of anthrax toxin genes in a Bacillus cereus associated with an illness resembling inhalation anthrax

P304

5425-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/IAI.00261-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P50

Conrad P. Quinn

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6193003

http://www.w3.org/2001/XMLSchema#string

P698

17646360

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

P932

2168292

http://www.w3.org/2001/XMLSchema#string